Skip to main content
. 2023 Apr 5;72(7):2443–2458. doi: 10.1007/s00262-023-03430-6

Table 1.

Baseline demographics and disease characteristics

Dose-escalation phase (n = 66) Expansion phase: oleclumab 40 mg/kg + durvalumab 10 mg/kg (n = 126)
Single-agent oleclumab 5–40 mg/kg (n = 42) Oleclumab 5–40 mg/kg + durvalumab 10 mg/kg (n = 24) MSS-CRC (n = 42) PDAC (n = 42) EGFRm NSCLC (n = 42)
Age, median (range), years 59.5 (36–81) 55 (32–71) 53 (25–80) 63.5 (32–77) 61.5 (34–83)
Sex, n (%)
 Male 20 (48) 9 (38) 19 (45) 16 (38) 17 (40)
 Female 22 (52) 15 (63) 23 (55) 26 (62) 25 (60)
Race, n (%)
 White 33 (79) 21 (88) 32 (76) 37 (88) 10 (24)
 Black or African American 3 (7) 2 (8) 4 (10) 1 (2) 1 (2)
 Asian 2 (5) 1 (4) 5 (12) 2 (5) 30 (71)
 Other 4 (10) 0 1 (2) 2 (5) 1 (2)a
ECOG PS, n (%)
 0 23 (55) 11 (46) 24 (57) 10 (24) 8 (19)
 1 19 (45) 13 (54) 18 (43) 32 (76) 34 (81)
Cancer type, n (%)
 CRCb 23 (55) 12 (50) 42 (100) 0 0
 PDAC 19 (45) 12 (50) 0 42 (100) 0
 EGFRm NSCLC 0 0 0 0 42 (100)
Time since initial diagnosis, median (range), months 26.1 (9.6–176.5) 31.5 (5.3–78.7) 36.7 (12.1–116.4) 14.8 (4.4–90.3) 26.0 (5.5–212.1)
Number of target lesions, median (range) 2 (1–5) 2 (1–5) 3 (1–5) 2 (1–5) 2 (1–5)
Prior lines of therapy,c n (%)
 1 2 (5) 4 (17) 1 (2) 15 (36) 9 (21)
 2 14 (33) 7 (29) 13 (31) 22 (52) 16 (38)
 3 16 (38) 7 (29) 12 (29) 5 (12) 11 (26)
 ≥ 4 10 (24) 6 (25) 16 (38) 0 6 (14)
Smoking history – yes, n (%) 16 (38) 8 (33) 12 (29) 10 (24) 12 (29)

ECOG PS Eastern Cooperative Oncology Group performance status, EGFRm epidermal growth factor receptor-mutant, MSI microsatellite instability, MSS-CRC microsatellite-stable colorectal cancer, NSCLC non-small-cell lung cancer, PDAC pancreatic ductal adenocarcinoma

aMultiple categories checked

bMSI status in patients with CRC was MSS for all patients with known status; unknown status in 11/23 (48%), 3/12 (25%), and 3/42 (7%) patients in the single-agent dose-escalation, combination dose-escalation, and CRC expansion cohorts, respectively

cAdjudicated